instruction stringlengths 34 186 | input stringlengths 2.02k 93.8k | output stringlengths 2 418 | meta_questiontype stringclasses 6
values | meta_inputlicense stringclasses 6
values | meta_pmid stringlengths 8 8 | meta_safetyreportid int64 9.51M 21M | meta_articlepubdate stringlengths 4 10 |
|---|---|---|---|---|---|---|---|
What was the dosage of drug 'PREDNISONE'? | SRP-positive necrotising myopathy: takes more than just the muscles.
Necrotising myopathy is an autoimmune disease that commonly affects muscles. Here we examine a case of a middle-aged women presenting with a chief report of shortness of breath, who subsequently developed muscle weakness. Her clinical course was compl... | UNKNOWN | DrugDosageText | CC BY-NC | 33608334 | 19,753,479 | 2021-02-19 |
What was the dosage of drug 'SIMVASTATIN'? | SRP-positive necrotising myopathy: takes more than just the muscles.
Necrotising myopathy is an autoimmune disease that commonly affects muscles. Here we examine a case of a middle-aged women presenting with a chief report of shortness of breath, who subsequently developed muscle weakness. Her clinical course was compl... | 40 mg (milligrams). | DrugDosage | CC BY-NC | 33608334 | 19,753,479 | 2021-02-19 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Adverse event'. | Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany.
Talimogene laherparepvec (T-VEC) is a licensed therapy for use in melanoma patients of stage IIIB-IVM1a with injectable, unresectable metastatic lesions in Europe. Approval was based on the Oncovex Piv... | TALIMOGENE LAHERPAREPVEC | DrugsGivenReaction | CC BY-NC | 33608376 | 18,948,777 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Arthralgia'. | Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany.
Talimogene laherparepvec (T-VEC) is a licensed therapy for use in melanoma patients of stage IIIB-IVM1a with injectable, unresectable metastatic lesions in Europe. Approval was based on the Oncovex Piv... | TALIMOGENE LAHERPAREPVEC | DrugsGivenReaction | CC BY-NC | 33608376 | 18,948,777 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cardiac disorder'. | Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany.
Talimogene laherparepvec (T-VEC) is a licensed therapy for use in melanoma patients of stage IIIB-IVM1a with injectable, unresectable metastatic lesions in Europe. Approval was based on the Oncovex Piv... | TALIMOGENE LAHERPAREPVEC | DrugsGivenReaction | CC BY-NC | 33608376 | 18,948,777 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Chills'. | Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany.
Talimogene laherparepvec (T-VEC) is a licensed therapy for use in melanoma patients of stage IIIB-IVM1a with injectable, unresectable metastatic lesions in Europe. Approval was based on the Oncovex Piv... | TALIMOGENE LAHERPAREPVEC | DrugsGivenReaction | CC BY-NC | 33608376 | 18,948,777 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Colitis'. | Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany.
Talimogene laherparepvec (T-VEC) is a licensed therapy for use in melanoma patients of stage IIIB-IVM1a with injectable, unresectable metastatic lesions in Europe. Approval was based on the Oncovex Piv... | TALIMOGENE LAHERPAREPVEC | DrugsGivenReaction | CC BY-NC | 33608376 | 18,948,777 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Death'. | Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany.
Talimogene laherparepvec (T-VEC) is a licensed therapy for use in melanoma patients of stage IIIB-IVM1a with injectable, unresectable metastatic lesions in Europe. Approval was based on the Oncovex Piv... | TALIMOGENE LAHERPAREPVEC | DrugsGivenReaction | CC BY-NC | 33608376 | 18,948,777 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Fatigue'. | Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany.
Talimogene laherparepvec (T-VEC) is a licensed therapy for use in melanoma patients of stage IIIB-IVM1a with injectable, unresectable metastatic lesions in Europe. Approval was based on the Oncovex Piv... | TALIMOGENE LAHERPAREPVEC | DrugsGivenReaction | CC BY-NC | 33608376 | 18,948,777 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Gastrointestinal disorder'. | Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany.
Talimogene laherparepvec (T-VEC) is a licensed therapy for use in melanoma patients of stage IIIB-IVM1a with injectable, unresectable metastatic lesions in Europe. Approval was based on the Oncovex Piv... | TALIMOGENE LAHERPAREPVEC | DrugsGivenReaction | CC BY-NC | 33608376 | 18,948,777 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Herpes virus infection'. | Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany.
Talimogene laherparepvec (T-VEC) is a licensed therapy for use in melanoma patients of stage IIIB-IVM1a with injectable, unresectable metastatic lesions in Europe. Approval was based on the Oncovex Piv... | TALIMOGENE LAHERPAREPVEC | DrugsGivenReaction | CC BY-NC | 33608376 | 18,948,777 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Injection site cellulitis'. | Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany.
Talimogene laherparepvec (T-VEC) is a licensed therapy for use in melanoma patients of stage IIIB-IVM1a with injectable, unresectable metastatic lesions in Europe. Approval was based on the Oncovex Piv... | TALIMOGENE LAHERPAREPVEC | DrugsGivenReaction | CC BY-NC | 33608376 | 18,948,777 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Injection site pain'. | Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany.
Talimogene laherparepvec (T-VEC) is a licensed therapy for use in melanoma patients of stage IIIB-IVM1a with injectable, unresectable metastatic lesions in Europe. Approval was based on the Oncovex Piv... | TALIMOGENE LAHERPAREPVEC | DrugsGivenReaction | CC BY-NC | 33608376 | 18,948,777 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Injection site reaction'. | Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany.
Talimogene laherparepvec (T-VEC) is a licensed therapy for use in melanoma patients of stage IIIB-IVM1a with injectable, unresectable metastatic lesions in Europe. Approval was based on the Oncovex Piv... | TALIMOGENE LAHERPAREPVEC | DrugsGivenReaction | CC BY-NC | 33608376 | 18,948,777 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Metastatic malignant melanoma'. | Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany.
Talimogene laherparepvec (T-VEC) is a licensed therapy for use in melanoma patients of stage IIIB-IVM1a with injectable, unresectable metastatic lesions in Europe. Approval was based on the Oncovex Piv... | TALIMOGENE LAHERPAREPVEC | DrugsGivenReaction | CC BY-NC | 33608376 | 18,948,777 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Nausea'. | Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany.
Talimogene laherparepvec (T-VEC) is a licensed therapy for use in melanoma patients of stage IIIB-IVM1a with injectable, unresectable metastatic lesions in Europe. Approval was based on the Oncovex Piv... | TALIMOGENE LAHERPAREPVEC | DrugsGivenReaction | CC BY-NC | 33608376 | 18,948,777 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany.
Talimogene laherparepvec (T-VEC) is a licensed therapy for use in melanoma patients of stage IIIB-IVM1a with injectable, unresectable metastatic lesions in Europe. Approval was based on the Oncovex Piv... | TALIMOGENE LAHERPAREPVEC | DrugsGivenReaction | CC BY-NC | 33608376 | 18,948,777 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Oral herpes'. | Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany.
Talimogene laherparepvec (T-VEC) is a licensed therapy for use in melanoma patients of stage IIIB-IVM1a with injectable, unresectable metastatic lesions in Europe. Approval was based on the Oncovex Piv... | TALIMOGENE LAHERPAREPVEC | DrugsGivenReaction | CC BY-NC | 33608376 | 18,948,777 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Pyrexia'. | Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany.
Talimogene laherparepvec (T-VEC) is a licensed therapy for use in melanoma patients of stage IIIB-IVM1a with injectable, unresectable metastatic lesions in Europe. Approval was based on the Oncovex Piv... | TALIMOGENE LAHERPAREPVEC | DrugsGivenReaction | CC BY-NC | 33608376 | 18,948,777 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Therapeutic product effect incomplete'. | Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany.
Talimogene laherparepvec (T-VEC) is a licensed therapy for use in melanoma patients of stage IIIB-IVM1a with injectable, unresectable metastatic lesions in Europe. Approval was based on the Oncovex Piv... | TALIMOGENE LAHERPAREPVEC | DrugsGivenReaction | CC BY-NC | 33608376 | 18,948,777 | 2021-02 |
What was the administration route of drug 'TALIMOGENE LAHERPAREPVEC'? | Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany.
Talimogene laherparepvec (T-VEC) is a licensed therapy for use in melanoma patients of stage IIIB-IVM1a with injectable, unresectable metastatic lesions in Europe. Approval was based on the Oncovex Piv... | Intratumor | DrugAdministrationRoute | CC BY-NC | 33608376 | 18,948,777 | 2021-02 |
What was the outcome of reaction 'Death'? | Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany.
Talimogene laherparepvec (T-VEC) is a licensed therapy for use in melanoma patients of stage IIIB-IVM1a with injectable, unresectable metastatic lesions in Europe. Approval was based on the Oncovex Piv... | Fatal | ReactionOutcome | CC BY-NC | 33608376 | 18,948,777 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neuroendocrine carcinoma of prostate'. | Treatment-emergent neuroendocrine prostate cancer with a germline BRCA2 mutation: identification of a candidate reversion mutation associated with platinum/PARP-inhibitor resistance.
Neuroendocrine prostate cancer (NEPC) is a highly aggressive histologic subtype of prostate cancer associated with a poor prognosis. Its ... | ABIRATERONE ACETATE, LEUPROLIDE ACETATE, PREDNISONE | DrugsGivenReaction | CC BY-NC | 33608381 | 18,972,244 | 2021-02 |
What was the administration route of drug 'ABIRATERONE ACETATE'? | Treatment-emergent neuroendocrine prostate cancer with a germline BRCA2 mutation: identification of a candidate reversion mutation associated with platinum/PARP-inhibitor resistance.
Neuroendocrine prostate cancer (NEPC) is a highly aggressive histologic subtype of prostate cancer associated with a poor prognosis. Its ... | Oral | DrugAdministrationRoute | CC BY-NC | 33608381 | 18,972,244 | 2021-02 |
What was the outcome of reaction 'Neuroendocrine carcinoma of prostate'? | Treatment-emergent neuroendocrine prostate cancer with a germline BRCA2 mutation: identification of a candidate reversion mutation associated with platinum/PARP-inhibitor resistance.
Neuroendocrine prostate cancer (NEPC) is a highly aggressive histologic subtype of prostate cancer associated with a poor prognosis. Its ... | Fatal | ReactionOutcome | CC BY-NC | 33608381 | 18,972,244 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Anaemia'. | The prevalence and clinical relevance of 2R/2R TYMS genotype in patients with gastrointestinal malignancies treated with fluoropyrimidine-based chemotherapy regimens.
The prevalence of 2R/2R TYMS genotype is variable but estimated to be around 20-30% in Caucasians. The clinical relevance of TYMS 2R/2R genotype in predi... | PANITUMUMAB | DrugsGivenReaction | CC BY | 33608662 | 20,129,181 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Diarrhoea'. | The prevalence and clinical relevance of 2R/2R TYMS genotype in patients with gastrointestinal malignancies treated with fluoropyrimidine-based chemotherapy regimens.
The prevalence of 2R/2R TYMS genotype is variable but estimated to be around 20-30% in Caucasians. The clinical relevance of TYMS 2R/2R genotype in predi... | PANITUMUMAB | DrugsGivenReaction | CC BY | 33608662 | 20,129,181 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Fatigue'. | The prevalence and clinical relevance of 2R/2R TYMS genotype in patients with gastrointestinal malignancies treated with fluoropyrimidine-based chemotherapy regimens.
The prevalence of 2R/2R TYMS genotype is variable but estimated to be around 20-30% in Caucasians. The clinical relevance of TYMS 2R/2R genotype in predi... | PANITUMUMAB | DrugsGivenReaction | CC BY | 33608662 | 20,129,181 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Mucosal inflammation'. | The prevalence and clinical relevance of 2R/2R TYMS genotype in patients with gastrointestinal malignancies treated with fluoropyrimidine-based chemotherapy regimens.
The prevalence of 2R/2R TYMS genotype is variable but estimated to be around 20-30% in Caucasians. The clinical relevance of TYMS 2R/2R genotype in predi... | PANITUMUMAB | DrugsGivenReaction | CC BY | 33608662 | 20,129,181 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Nausea'. | The prevalence and clinical relevance of 2R/2R TYMS genotype in patients with gastrointestinal malignancies treated with fluoropyrimidine-based chemotherapy regimens.
The prevalence of 2R/2R TYMS genotype is variable but estimated to be around 20-30% in Caucasians. The clinical relevance of TYMS 2R/2R genotype in predi... | PANITUMUMAB | DrugsGivenReaction | CC BY | 33608662 | 20,129,181 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neurotoxicity'. | The prevalence and clinical relevance of 2R/2R TYMS genotype in patients with gastrointestinal malignancies treated with fluoropyrimidine-based chemotherapy regimens.
The prevalence of 2R/2R TYMS genotype is variable but estimated to be around 20-30% in Caucasians. The clinical relevance of TYMS 2R/2R genotype in predi... | PANITUMUMAB | DrugsGivenReaction | CC BY | 33608662 | 20,129,181 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Neutropenia'. | The prevalence and clinical relevance of 2R/2R TYMS genotype in patients with gastrointestinal malignancies treated with fluoropyrimidine-based chemotherapy regimens.
The prevalence of 2R/2R TYMS genotype is variable but estimated to be around 20-30% in Caucasians. The clinical relevance of TYMS 2R/2R genotype in predi... | PANITUMUMAB | DrugsGivenReaction | CC BY | 33608662 | 20,129,181 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Skin toxicity'. | The prevalence and clinical relevance of 2R/2R TYMS genotype in patients with gastrointestinal malignancies treated with fluoropyrimidine-based chemotherapy regimens.
The prevalence of 2R/2R TYMS genotype is variable but estimated to be around 20-30% in Caucasians. The clinical relevance of TYMS 2R/2R genotype in predi... | PANITUMUMAB | DrugsGivenReaction | CC BY | 33608662 | 20,129,181 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Thrombocytopenia'. | The prevalence and clinical relevance of 2R/2R TYMS genotype in patients with gastrointestinal malignancies treated with fluoropyrimidine-based chemotherapy regimens.
The prevalence of 2R/2R TYMS genotype is variable but estimated to be around 20-30% in Caucasians. The clinical relevance of TYMS 2R/2R genotype in predi... | PANITUMUMAB | DrugsGivenReaction | CC BY | 33608662 | 20,129,181 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Vasospasm'. | The prevalence and clinical relevance of 2R/2R TYMS genotype in patients with gastrointestinal malignancies treated with fluoropyrimidine-based chemotherapy regimens.
The prevalence of 2R/2R TYMS genotype is variable but estimated to be around 20-30% in Caucasians. The clinical relevance of TYMS 2R/2R genotype in predi... | PANITUMUMAB | DrugsGivenReaction | CC BY | 33608662 | 20,129,181 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Vomiting'. | The prevalence and clinical relevance of 2R/2R TYMS genotype in patients with gastrointestinal malignancies treated with fluoropyrimidine-based chemotherapy regimens.
The prevalence of 2R/2R TYMS genotype is variable but estimated to be around 20-30% in Caucasians. The clinical relevance of TYMS 2R/2R genotype in predi... | PANITUMUMAB | DrugsGivenReaction | CC BY | 33608662 | 20,129,181 | 2021-06 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cell death'. | Ambulatory high-dose methotrexate administration as central nervous system prophylaxis in patients with aggressive lymphoma.
High-dose methotrexate (HD-MTX) at 3 g/m2 is one of the strategies for central nervous system (CNS) prophylaxis in the first-line treatment of aggressive lymphomas, especially in diffuse large B ... | METHOTREXATE | DrugsGivenReaction | CC BY | 33608849 | 18,968,535 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Gastrointestinal toxicity'. | Ambulatory high-dose methotrexate administration as central nervous system prophylaxis in patients with aggressive lymphoma.
High-dose methotrexate (HD-MTX) at 3 g/m2 is one of the strategies for central nervous system (CNS) prophylaxis in the first-line treatment of aggressive lymphomas, especially in diffuse large B ... | METHOTREXATE | DrugsGivenReaction | CC BY | 33608849 | 18,967,953 | 2021-04 |
What was the dosage of drug 'METHOTREXATE'? | Ambulatory high-dose methotrexate administration as central nervous system prophylaxis in patients with aggressive lymphoma.
High-dose methotrexate (HD-MTX) at 3 g/m2 is one of the strategies for central nervous system (CNS) prophylaxis in the first-line treatment of aggressive lymphomas, especially in diffuse large B ... | HD?MTX (3 G/M2) | DrugDosageText | CC BY | 33608849 | 18,968,535 | 2021-04 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Aortic aneurysm'. | Infected thoracoabdominal aortic aneurysm related to an implanted long-term arterial catheter for chemotherapy: a case report.
BACKGROUND
An infected aortic aneurysm is a rare and life-threatening vascular condition with a high incidence of arterial rupture and recurrence even after treatment. One of the most common ca... | BEVACIZUMAB, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN | DrugsGivenReaction | CC BY | 33610163 | 19,648,394 | 2021-02-21 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Back pain'. | Infected thoracoabdominal aortic aneurysm related to an implanted long-term arterial catheter for chemotherapy: a case report.
BACKGROUND
An infected aortic aneurysm is a rare and life-threatening vascular condition with a high incidence of arterial rupture and recurrence even after treatment. One of the most common ca... | BEVACIZUMAB, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN | DrugsGivenReaction | CC BY | 33610163 | 19,648,394 | 2021-02-21 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Device related infection'. | Infected thoracoabdominal aortic aneurysm related to an implanted long-term arterial catheter for chemotherapy: a case report.
BACKGROUND
An infected aortic aneurysm is a rare and life-threatening vascular condition with a high incidence of arterial rupture and recurrence even after treatment. One of the most common ca... | BEVACIZUMAB, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN | DrugsGivenReaction | CC BY | 33610163 | 19,648,394 | 2021-02-21 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Hepatic artery aneurysm'. | Infected thoracoabdominal aortic aneurysm related to an implanted long-term arterial catheter for chemotherapy: a case report.
BACKGROUND
An infected aortic aneurysm is a rare and life-threatening vascular condition with a high incidence of arterial rupture and recurrence even after treatment. One of the most common ca... | BEVACIZUMAB, FLUOROURACIL, LEUCOVORIN, OXALIPLATIN | DrugsGivenReaction | CC BY | 33610163 | 19,648,394 | 2021-02-21 |
What was the outcome of reaction 'Aortic aneurysm'? | Infected thoracoabdominal aortic aneurysm related to an implanted long-term arterial catheter for chemotherapy: a case report.
BACKGROUND
An infected aortic aneurysm is a rare and life-threatening vascular condition with a high incidence of arterial rupture and recurrence even after treatment. One of the most common ca... | Recovered | ReactionOutcome | CC BY | 33610163 | 19,648,394 | 2021-02-21 |
What was the outcome of reaction 'Back pain'? | Infected thoracoabdominal aortic aneurysm related to an implanted long-term arterial catheter for chemotherapy: a case report.
BACKGROUND
An infected aortic aneurysm is a rare and life-threatening vascular condition with a high incidence of arterial rupture and recurrence even after treatment. One of the most common ca... | Recovered | ReactionOutcome | CC BY | 33610163 | 19,648,394 | 2021-02-21 |
What was the outcome of reaction 'Device related infection'? | Infected thoracoabdominal aortic aneurysm related to an implanted long-term arterial catheter for chemotherapy: a case report.
BACKGROUND
An infected aortic aneurysm is a rare and life-threatening vascular condition with a high incidence of arterial rupture and recurrence even after treatment. One of the most common ca... | Recovered | ReactionOutcome | CC BY | 33610163 | 19,648,394 | 2021-02-21 |
What was the outcome of reaction 'Hepatic artery aneurysm'? | Infected thoracoabdominal aortic aneurysm related to an implanted long-term arterial catheter for chemotherapy: a case report.
BACKGROUND
An infected aortic aneurysm is a rare and life-threatening vascular condition with a high incidence of arterial rupture and recurrence even after treatment. One of the most common ca... | Recovered | ReactionOutcome | CC BY | 33610163 | 19,648,394 | 2021-02-21 |
What was the administration route of drug 'DEXTROSE'? | Burkitt lymphoma and lactic acidosis: A case report and review of the literature.
Type A lactic acidosis is a potentially life-threatening complication in critically ill patients and is the hallmark of a shock state as a result of tissue hypoperfusion and dysoxia. Type B lactic acidosis results from mechanisms other th... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY | 33611854 | 19,181,715 | 2021-02 |
What was the administration route of drug 'METHOTREXATE SODIUM'? | Burkitt lymphoma and lactic acidosis: A case report and review of the literature.
Type A lactic acidosis is a potentially life-threatening complication in critically ill patients and is the hallmark of a shock state as a result of tissue hypoperfusion and dysoxia. Type B lactic acidosis results from mechanisms other th... | Intrathecal | DrugAdministrationRoute | CC BY | 33611854 | 19,126,628 | 2021-02 |
What was the administration route of drug 'METHOTREXATE'? | Burkitt lymphoma and lactic acidosis: A case report and review of the literature.
Type A lactic acidosis is a potentially life-threatening complication in critically ill patients and is the hallmark of a shock state as a result of tissue hypoperfusion and dysoxia. Type B lactic acidosis results from mechanisms other th... | Intrathecal | DrugAdministrationRoute | CC BY | 33611854 | 19,163,699 | 2021-02 |
What was the dosage of drug 'DOXORUBICIN'? | Burkitt lymphoma and lactic acidosis: A case report and review of the literature.
Type A lactic acidosis is a potentially life-threatening complication in critically ill patients and is the hallmark of a shock state as a result of tissue hypoperfusion and dysoxia. Type B lactic acidosis results from mechanisms other th... | UNK, CYCLICAL | DrugDosageText | CC BY | 33611854 | 19,163,699 | 2021-02 |
What was the dosage of drug 'METHOTREXATE SODIUM'? | Burkitt lymphoma and lactic acidosis: A case report and review of the literature.
Type A lactic acidosis is a potentially life-threatening complication in critically ill patients and is the hallmark of a shock state as a result of tissue hypoperfusion and dysoxia. Type B lactic acidosis results from mechanisms other th... | 10 DF | DrugDosageText | CC BY | 33611854 | 19,126,628 | 2021-02 |
What was the dosage of drug 'PREDNISOLONE'? | Burkitt lymphoma and lactic acidosis: A case report and review of the literature.
Type A lactic acidosis is a potentially life-threatening complication in critically ill patients and is the hallmark of a shock state as a result of tissue hypoperfusion and dysoxia. Type B lactic acidosis results from mechanisms other th... | UNK, CYCLICAL | DrugDosageText | CC BY | 33611854 | 19,163,699 | 2021-02 |
What was the outcome of reaction 'Agranulocytosis'? | Burkitt lymphoma and lactic acidosis: A case report and review of the literature.
Type A lactic acidosis is a potentially life-threatening complication in critically ill patients and is the hallmark of a shock state as a result of tissue hypoperfusion and dysoxia. Type B lactic acidosis results from mechanisms other th... | Recovered | ReactionOutcome | CC BY | 33611854 | 19,114,934 | 2021-02 |
What was the outcome of reaction 'Anaemia'? | Burkitt lymphoma and lactic acidosis: A case report and review of the literature.
Type A lactic acidosis is a potentially life-threatening complication in critically ill patients and is the hallmark of a shock state as a result of tissue hypoperfusion and dysoxia. Type B lactic acidosis results from mechanisms other th... | Recovered | ReactionOutcome | CC BY | 33611854 | 19,114,934 | 2021-02 |
What was the outcome of reaction 'Pyrexia'? | Burkitt lymphoma and lactic acidosis: A case report and review of the literature.
Type A lactic acidosis is a potentially life-threatening complication in critically ill patients and is the hallmark of a shock state as a result of tissue hypoperfusion and dysoxia. Type B lactic acidosis results from mechanisms other th... | Recovered | ReactionOutcome | CC BY | 33611854 | 19,181,715 | 2021-02 |
What was the outcome of reaction 'Thrombocytopenia'? | Burkitt lymphoma and lactic acidosis: A case report and review of the literature.
Type A lactic acidosis is a potentially life-threatening complication in critically ill patients and is the hallmark of a shock state as a result of tissue hypoperfusion and dysoxia. Type B lactic acidosis results from mechanisms other th... | Recovered | ReactionOutcome | CC BY | 33611854 | 19,114,934 | 2021-02 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'COVID-19'. | Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic
To evaluate treatment adherence and predictors of drug discontinuation among patients with inflammatory arthritis
receiving bDMARDs within the first 100 days after the annou... | ADALIMUMAB | DrugsGivenReaction | CC BY | 33611869 | 20,063,722 | 2021-08-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic
To evaluate treatment adherence and predictors of drug discontinuation among patients with inflammatory arthritis
receiving bDMARDs within the first 100 days after the annou... | ADALIMUMAB | DrugsGivenReaction | CC BY | 33611869 | 20,063,722 | 2021-08-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Psoriatic arthropathy'. | Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic
To evaluate treatment adherence and predictors of drug discontinuation among patients with inflammatory arthritis
receiving bDMARDs within the first 100 days after the annou... | ADALIMUMAB | DrugsGivenReaction | CC BY | 33611869 | 20,063,722 | 2021-08-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Rheumatoid arthritis'. | Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic
To evaluate treatment adherence and predictors of drug discontinuation among patients with inflammatory arthritis
receiving bDMARDs within the first 100 days after the annou... | ADALIMUMAB | DrugsGivenReaction | CC BY | 33611869 | 20,063,722 | 2021-08-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Unevaluable event'. | Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic
To evaluate treatment adherence and predictors of drug discontinuation among patients with inflammatory arthritis
receiving bDMARDs within the first 100 days after the annou... | ADALIMUMAB | DrugsGivenReaction | CC BY | 33611869 | 20,063,722 | 2021-08-30 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Malignant neoplasm progression'. | Rapidly Progressing Anaplastic Carcinoma of the Pancreas with Mucoepidermoid Carcinoma: An Autopsy Case Report.
A 75-year-old man visited our hospital for the examination of a tumor in the pancreas. Computed tomography showed an 85×85-mm low-density tumor in the pancreas. The tumor was pathologically diagnosed as poorl... | GEMCITABINE, PACLITAXEL | DrugsGivenReaction | CC BY-NC-ND | 33612673 | 20,737,963 | 2021-07-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Reversible cerebral vasoconstriction syndrome'. | Reversible Cerebral Vasoconstriction Syndrome without Headache That Was Initially Suspected of Being Primary Angiitis of the Central Nervous System.
A 48-year-old man had convulsions, and magnetic resonance angiography (MRA) showed diffuse constriction of the cerebral arteries. He was suspected of having primary angiit... | ACYCLOVIR, AMLODIPINE BESYLATE, APREMILAST, LEVETIRACETAM, TELMISARTAN | DrugsGivenReaction | CC BY-NC-ND | 33612678 | 19,735,583 | 2021-07-15 |
What was the administration route of drug 'ACYCLOVIR'? | Reversible Cerebral Vasoconstriction Syndrome without Headache That Was Initially Suspected of Being Primary Angiitis of the Central Nervous System.
A 48-year-old man had convulsions, and magnetic resonance angiography (MRA) showed diffuse constriction of the cerebral arteries. He was suspected of having primary angiit... | Intravenous (not otherwise specified) | DrugAdministrationRoute | CC BY-NC-ND | 33612678 | 19,735,583 | 2021-07-15 |
What was the administration route of drug 'APREMILAST'? | Reversible Cerebral Vasoconstriction Syndrome without Headache That Was Initially Suspected of Being Primary Angiitis of the Central Nervous System.
A 48-year-old man had convulsions, and magnetic resonance angiography (MRA) showed diffuse constriction of the cerebral arteries. He was suspected of having primary angiit... | Oral | DrugAdministrationRoute | CC BY-NC-ND | 33612678 | 19,735,583 | 2021-07-15 |
What was the dosage of drug 'ACYCLOVIR'? | Reversible Cerebral Vasoconstriction Syndrome without Headache That Was Initially Suspected of Being Primary Angiitis of the Central Nervous System.
A 48-year-old man had convulsions, and magnetic resonance angiography (MRA) showed diffuse constriction of the cerebral arteries. He was suspected of having primary angiit... | 10 MILLIGRAM/KILOGRAM, Q8H | DrugDosageText | CC BY-NC-ND | 33612678 | 19,735,583 | 2021-07-15 |
What was the dosage of drug 'APREMILAST'? | Reversible Cerebral Vasoconstriction Syndrome without Headache That Was Initially Suspected of Being Primary Angiitis of the Central Nervous System.
A 48-year-old man had convulsions, and magnetic resonance angiography (MRA) showed diffuse constriction of the cerebral arteries. He was suspected of having primary angiit... | 30 MILLIGRAM, BID | DrugDosageText | CC BY-NC-ND | 33612678 | 19,735,583 | 2021-07-15 |
What was the outcome of reaction 'Reversible cerebral vasoconstriction syndrome'? | Reversible Cerebral Vasoconstriction Syndrome without Headache That Was Initially Suspected of Being Primary Angiitis of the Central Nervous System.
A 48-year-old man had convulsions, and magnetic resonance angiography (MRA) showed diffuse constriction of the cerebral arteries. He was suspected of having primary angiit... | Recovering | ReactionOutcome | CC BY-NC-ND | 33612678 | 19,735,583 | 2021-07-15 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug-induced liver injury'. | Severe Liver Injury Associated with Glecaprevir Plus Pibrentasvir Therapy in a Patient with Treatment-naïve Hepatitis C Virus Infection.
A 49-year-old man underwent treatment with glecaprevir plus pibrentasvir (G/P) for chronic hepatitis C infection. Six weeks later, he was admitted to our hospital because of jaundice ... | BROTIZOLAM, ESOMEPRAZOLE MAGNESIUM, ETIZOLAM, GLECAPREVIR\PIBRENTASVIR | DrugsGivenReaction | CC BY-NC-ND | 33612683 | 19,682,017 | 2021-08-01 |
What is the weight of the patient? | Severe Liver Injury Associated with Glecaprevir Plus Pibrentasvir Therapy in a Patient with Treatment-naïve Hepatitis C Virus Infection.
A 49-year-old man underwent treatment with glecaprevir plus pibrentasvir (G/P) for chronic hepatitis C infection. Six weeks later, he was admitted to our hospital because of jaundice ... | 77.2 kg. | Weight | CC BY-NC-ND | 33612683 | 19,682,017 | 2021-08-01 |
What was the administration route of drug 'GLECAPREVIR\PIBRENTASVIR'? | Severe Liver Injury Associated with Glecaprevir Plus Pibrentasvir Therapy in a Patient with Treatment-naïve Hepatitis C Virus Infection.
A 49-year-old man underwent treatment with glecaprevir plus pibrentasvir (G/P) for chronic hepatitis C infection. Six weeks later, he was admitted to our hospital because of jaundice ... | Oral | DrugAdministrationRoute | CC BY-NC-ND | 33612683 | 19,682,017 | 2021-08-01 |
What was the dosage of drug 'GLECAPREVIR\PIBRENTASVIR'? | Severe Liver Injury Associated with Glecaprevir Plus Pibrentasvir Therapy in a Patient with Treatment-naïve Hepatitis C Virus Infection.
A 49-year-old man underwent treatment with glecaprevir plus pibrentasvir (G/P) for chronic hepatitis C infection. Six weeks later, he was admitted to our hospital because of jaundice ... | 100/40 MG | DrugDosageText | CC BY-NC-ND | 33612683 | 19,682,017 | 2021-08-01 |
What was the outcome of reaction 'Drug-induced liver injury'? | Severe Liver Injury Associated with Glecaprevir Plus Pibrentasvir Therapy in a Patient with Treatment-naïve Hepatitis C Virus Infection.
A 49-year-old man underwent treatment with glecaprevir plus pibrentasvir (G/P) for chronic hepatitis C infection. Six weeks later, he was admitted to our hospital because of jaundice ... | Recovering | ReactionOutcome | CC BY-NC-ND | 33612683 | 19,682,017 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Granulocyte and Monocyte Adsorptive Apheresis for Ulcerative Colitis in a Patient with Low Bone Mineral Density Due to Fanconi-Bickel Syndrome.
Systemic steroid is required for the exacerbation of ulcerative colitis (UC), although its administration should be avoided in patients with a low bone mineral density (BMD) ex... | MESALAMINE, SULFASALAZINE | DrugsGivenReaction | CC BY-NC-ND | 33612684 | 19,785,330 | 2021-08-01 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective for unapproved indication'. | Intralymphatic Histiocytosis: An Unusual Presentation.
Intralymphatic histiocytosis (ILH) is a rare cutaneous condition initially described in 1994 by O'Grady et al. It often appears as a red to violaceous, livedoid patch or plaque usually on the extremities. We present a 71-year-old female with a history of psoriasis,... | PENTOXIFYLLINE, TACROLIMUS | DrugsGivenReaction | CC BY-NC | 33613226 | 19,720,171 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Off label use'. | Intralymphatic Histiocytosis: An Unusual Presentation.
Intralymphatic histiocytosis (ILH) is a rare cutaneous condition initially described in 1994 by O'Grady et al. It often appears as a red to violaceous, livedoid patch or plaque usually on the extremities. We present a 71-year-old female with a history of psoriasis,... | PENTOXIFYLLINE, TACROLIMUS | DrugsGivenReaction | CC BY-NC | 33613226 | 19,720,171 | 2021 |
What was the administration route of drug 'PENTOXIFYLLINE'? | Intralymphatic Histiocytosis: An Unusual Presentation.
Intralymphatic histiocytosis (ILH) is a rare cutaneous condition initially described in 1994 by O'Grady et al. It often appears as a red to violaceous, livedoid patch or plaque usually on the extremities. We present a 71-year-old female with a history of psoriasis,... | Oral | DrugAdministrationRoute | CC BY-NC | 33613226 | 19,720,171 | 2021 |
What was the administration route of drug 'TACROLIMUS'? | Intralymphatic Histiocytosis: An Unusual Presentation.
Intralymphatic histiocytosis (ILH) is a rare cutaneous condition initially described in 1994 by O'Grady et al. It often appears as a red to violaceous, livedoid patch or plaque usually on the extremities. We present a 71-year-old female with a history of psoriasis,... | Topical | DrugAdministrationRoute | CC BY-NC | 33613226 | 19,720,171 | 2021 |
What was the dosage of drug 'TACROLIMUS'? | Intralymphatic Histiocytosis: An Unusual Presentation.
Intralymphatic histiocytosis (ILH) is a rare cutaneous condition initially described in 1994 by O'Grady et al. It often appears as a red to violaceous, livedoid patch or plaque usually on the extremities. We present a 71-year-old female with a history of psoriasis,... | UNK UNK, BID | DrugDosageText | CC BY-NC | 33613226 | 19,720,171 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Bladder tamponade'. | BK Virus-Associated Urothelial Carcinoma in a Patient with Peripheral Blood Stem Cell Transplantation for Acute Lymphoblastic Leukemia: A Case Report.
Bladder tamponade due to hemorrhagic cystitis caused by BK virus in immunocompetent patients is familiar to urologists. BK virus is an important cause of nephropathy and... | ASPARAGINASE, BUSULFAN, CYCLOPHOSPHAMIDE, DAUNORUBICIN, FLUDARABINE PHOSPHATE, MYCOPHENOLIC ACID, TACROLIMUS, VINCRISTINE | DrugsGivenReaction | CC BY-NC | 33613235 | 19,452,922 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Haematotoxicity'. | BK Virus-Associated Urothelial Carcinoma in a Patient with Peripheral Blood Stem Cell Transplantation for Acute Lymphoblastic Leukemia: A Case Report.
Bladder tamponade due to hemorrhagic cystitis caused by BK virus in immunocompetent patients is familiar to urologists. BK virus is an important cause of nephropathy and... | ASPARAGINASE, BUSULFAN, CYCLOPHOSPHAMIDE, DAUNORUBICIN, FLUDARABINE PHOSPHATE, MYCOPHENOLIC ACID, TACROLIMUS, VINCRISTINE | DrugsGivenReaction | CC BY-NC | 33613235 | 19,452,922 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Haematuria'. | BK Virus-Associated Urothelial Carcinoma in a Patient with Peripheral Blood Stem Cell Transplantation for Acute Lymphoblastic Leukemia: A Case Report.
Bladder tamponade due to hemorrhagic cystitis caused by BK virus in immunocompetent patients is familiar to urologists. BK virus is an important cause of nephropathy and... | ASPARAGINASE, BUSULFAN, CYCLOPHOSPHAMIDE, DAUNORUBICIN, FLUDARABINE PHOSPHATE, MYCOPHENOLIC ACID, TACROLIMUS, VINCRISTINE | DrugsGivenReaction | CC BY-NC | 33613235 | 19,452,922 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Platelet count decreased'. | BK Virus-Associated Urothelial Carcinoma in a Patient with Peripheral Blood Stem Cell Transplantation for Acute Lymphoblastic Leukemia: A Case Report.
Bladder tamponade due to hemorrhagic cystitis caused by BK virus in immunocompetent patients is familiar to urologists. BK virus is an important cause of nephropathy and... | ASPARAGINASE, BUSULFAN, CYCLOPHOSPHAMIDE, DAUNORUBICIN, FLUDARABINE PHOSPHATE, MYCOPHENOLIC ACID, TACROLIMUS, VINCRISTINE | DrugsGivenReaction | CC BY-NC | 33613235 | 19,452,922 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Viral haemorrhagic cystitis'. | BK Virus-Associated Urothelial Carcinoma in a Patient with Peripheral Blood Stem Cell Transplantation for Acute Lymphoblastic Leukemia: A Case Report.
Bladder tamponade due to hemorrhagic cystitis caused by BK virus in immunocompetent patients is familiar to urologists. BK virus is an important cause of nephropathy and... | ASPARAGINASE, BUSULFAN, CYCLOPHOSPHAMIDE, DAUNORUBICIN, FLUDARABINE PHOSPHATE, MYCOPHENOLIC ACID, TACROLIMUS, VINCRISTINE | DrugsGivenReaction | CC BY-NC | 33613235 | 19,452,922 | 2021 |
What was the dosage of drug 'CYCLOPHOSPHAMIDE'? | BK Virus-Associated Urothelial Carcinoma in a Patient with Peripheral Blood Stem Cell Transplantation for Acute Lymphoblastic Leukemia: A Case Report.
Bladder tamponade due to hemorrhagic cystitis caused by BK virus in immunocompetent patients is familiar to urologists. BK virus is an important cause of nephropathy and... | POSTTRANSPLANT CYCLOPHOSPHAMIDE | DrugDosageText | CC BY-NC | 33613235 | 19,452,922 | 2021 |
What was the dosage of drug 'MYCOPHENOLIC ACID'? | BK Virus-Associated Urothelial Carcinoma in a Patient with Peripheral Blood Stem Cell Transplantation for Acute Lymphoblastic Leukemia: A Case Report.
Bladder tamponade due to hemorrhagic cystitis caused by BK virus in immunocompetent patients is familiar to urologists. BK virus is an important cause of nephropathy and... | USED FOR HALF A YEAR BEFORE TRANSPLANTATION | DrugDosageText | CC BY-NC | 33613235 | 19,452,922 | 2021 |
What was the dosage of drug 'TACROLIMUS'? | BK Virus-Associated Urothelial Carcinoma in a Patient with Peripheral Blood Stem Cell Transplantation for Acute Lymphoblastic Leukemia: A Case Report.
Bladder tamponade due to hemorrhagic cystitis caused by BK virus in immunocompetent patients is familiar to urologists. BK virus is an important cause of nephropathy and... | USED FOR HALF A YEAR BEFORE TRANSPLANTATION | DrugDosageText | CC BY-NC | 33613235 | 19,452,922 | 2021 |
What was the outcome of reaction 'BK virus infection'? | BK Virus-Associated Urothelial Carcinoma in a Patient with Peripheral Blood Stem Cell Transplantation for Acute Lymphoblastic Leukemia: A Case Report.
Bladder tamponade due to hemorrhagic cystitis caused by BK virus in immunocompetent patients is familiar to urologists. BK virus is an important cause of nephropathy and... | Recovered | ReactionOutcome | CC BY-NC | 33613235 | 19,468,926 | 2021 |
What was the outcome of reaction 'Bladder tamponade'? | BK Virus-Associated Urothelial Carcinoma in a Patient with Peripheral Blood Stem Cell Transplantation for Acute Lymphoblastic Leukemia: A Case Report.
Bladder tamponade due to hemorrhagic cystitis caused by BK virus in immunocompetent patients is familiar to urologists. BK virus is an important cause of nephropathy and... | Recovered | ReactionOutcome | CC BY-NC | 33613235 | 19,452,922 | 2021 |
What was the outcome of reaction 'Haematotoxicity'? | BK Virus-Associated Urothelial Carcinoma in a Patient with Peripheral Blood Stem Cell Transplantation for Acute Lymphoblastic Leukemia: A Case Report.
Bladder tamponade due to hemorrhagic cystitis caused by BK virus in immunocompetent patients is familiar to urologists. BK virus is an important cause of nephropathy and... | Recovered | ReactionOutcome | CC BY-NC | 33613235 | 19,452,922 | 2021 |
What was the outcome of reaction 'Haematuria'? | BK Virus-Associated Urothelial Carcinoma in a Patient with Peripheral Blood Stem Cell Transplantation for Acute Lymphoblastic Leukemia: A Case Report.
Bladder tamponade due to hemorrhagic cystitis caused by BK virus in immunocompetent patients is familiar to urologists. BK virus is an important cause of nephropathy and... | Recovered | ReactionOutcome | CC BY-NC | 33613235 | 19,452,922 | 2021 |
What was the outcome of reaction 'Infection reactivation'? | BK Virus-Associated Urothelial Carcinoma in a Patient with Peripheral Blood Stem Cell Transplantation for Acute Lymphoblastic Leukemia: A Case Report.
Bladder tamponade due to hemorrhagic cystitis caused by BK virus in immunocompetent patients is familiar to urologists. BK virus is an important cause of nephropathy and... | Recovered | ReactionOutcome | CC BY-NC | 33613235 | 19,468,926 | 2021 |
What was the outcome of reaction 'Myelosuppression'? | BK Virus-Associated Urothelial Carcinoma in a Patient with Peripheral Blood Stem Cell Transplantation for Acute Lymphoblastic Leukemia: A Case Report.
Bladder tamponade due to hemorrhagic cystitis caused by BK virus in immunocompetent patients is familiar to urologists. BK virus is an important cause of nephropathy and... | Recovered | ReactionOutcome | CC BY-NC | 33613235 | 19,452,922 | 2021 |
What was the outcome of reaction 'Platelet count decreased'? | BK Virus-Associated Urothelial Carcinoma in a Patient with Peripheral Blood Stem Cell Transplantation for Acute Lymphoblastic Leukemia: A Case Report.
Bladder tamponade due to hemorrhagic cystitis caused by BK virus in immunocompetent patients is familiar to urologists. BK virus is an important cause of nephropathy and... | Recovered | ReactionOutcome | CC BY-NC | 33613235 | 19,452,922 | 2021 |
What was the outcome of reaction 'Transitional cell carcinoma'? | BK Virus-Associated Urothelial Carcinoma in a Patient with Peripheral Blood Stem Cell Transplantation for Acute Lymphoblastic Leukemia: A Case Report.
Bladder tamponade due to hemorrhagic cystitis caused by BK virus in immunocompetent patients is familiar to urologists. BK virus is an important cause of nephropathy and... | Recovered | ReactionOutcome | CC BY-NC | 33613235 | 19,468,926 | 2021 |
What was the outcome of reaction 'Viral haemorrhagic cystitis'? | BK Virus-Associated Urothelial Carcinoma in a Patient with Peripheral Blood Stem Cell Transplantation for Acute Lymphoblastic Leukemia: A Case Report.
Bladder tamponade due to hemorrhagic cystitis caused by BK virus in immunocompetent patients is familiar to urologists. BK virus is an important cause of nephropathy and... | Recovered | ReactionOutcome | CC BY-NC | 33613235 | 19,452,922 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Cerebellar atrophy'. | Anti-N-Methyl-D-Aspartate Receptor Encephalitis with Decrease in Blood Flow in Cerebellum.
In anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis, progressive cerebellar atrophy potentially leads to severe sequelae. We encountered a patient with anti-NMDAR antibody encephalitis who showed a decrease of blood flow i... | METHOTREXATE | DrugsGivenReaction | CC BY-NC | 33613239 | 19,793,498 | 2021 |
Give an alphabetized list of all active substances of drugs taken by the patient who experienced 'Drug ineffective'. | Anti-N-Methyl-D-Aspartate Receptor Encephalitis with Decrease in Blood Flow in Cerebellum.
In anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis, progressive cerebellar atrophy potentially leads to severe sequelae. We encountered a patient with anti-NMDAR antibody encephalitis who showed a decrease of blood flow i... | METHOTREXATE | DrugsGivenReaction | CC BY-NC | 33613239 | 19,793,498 | 2021 |
What was the administration route of drug 'METHOTREXATE'? | Anti-N-Methyl-D-Aspartate Receptor Encephalitis with Decrease in Blood Flow in Cerebellum.
In anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis, progressive cerebellar atrophy potentially leads to severe sequelae. We encountered a patient with anti-NMDAR antibody encephalitis who showed a decrease of blood flow i... | Oral | DrugAdministrationRoute | CC BY-NC | 33613239 | 19,793,498 | 2021 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.